基于患者路径的耐多药结核病诊疗结局及其影响因素的分析  

Diagnosis and Treatment Outcomes and Influencing Factors of Multidrug-Resistant Tuberculosis Based on Patient Pathway

作　　者：任艳丽 陈彬[2] 蒋健敏[1,2] REN Yanli;CHEN Bin;JIANG Jianmin(School of Public Health,Hangzhou Normal University,Hangzhou 311121,China;Tuberculosis Prevention and Control Institute,Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310021,China)

机构地区：[1]杭州师范大学公共卫生学院,杭州311121 [2]浙江省疾病预防控制中心结核病防治所,杭州310021

出　　处：《中国医学科学院学报》2023年第2期178-184,共7页Acta Academiae Medicinae Sinicae

基　　金：国家卫生健康委科学研究基金-省部共建计划重点项目(WKJ-ZJ-2118)。

摘　　要：耐多药结核病(MDR-TB)已成为全球结核病防治工作的主要挑战之一。尽管我国MDR-TB防治工作已开展多年,但治疗成功率提升缓慢,提示在防治工作质量上可能存在管理的不足。因此,基于患者路径来分析MDR-TB防治现状是十分必要的。本文总结了在诊疗路径中的MDR-TB患者脱失现状和在全路径中影响患者转归的因素,为MDR-TB防控提供参考。Multidrug-resistant tuberculosis(MDR-TB)has become one of the major challenges in the global tuberculosis(TB)control.Despite years of efforts on MDR-TB control,the treatment success rates in China have increased slowly,which indicates possible deficiencies in the management of prevention and control work.Therefore,it is necessary to analyze the current status of MDR-TB prevention and treatment based on the patient pathway.This review summarizes the current drop-out situation of MDR-TB patients in the diagnosis and treatment pathway and the factors affecting patients’outcomes in the whole pathway,so as to provide a scientific reference for the prevention and control of MDR-TB.

关 键 词：耐多药结核病 患者路径 影响因素 结核病 

分 类 号：R183.3[医药卫生—流行病学]